title: Preoperative epoetin alfa vs autologous blood donation in primary total knee arthroplasty.
abstract: This prospective randomized trial compared preoperative autologous blood donation (PAD) with epoetin alfa in patients undergoing primary total knee reconstruction. Fifty adult patients with pretreatment hemoglobin level of 100 to 130 g/L were randomized to either epoetin alfa 40,000 U at preoperative days 14 and 7 or to a standard PAD protocol. Patient characteristics and operative blood loss were similar between groups. Baseline hematological parameters for epoetin alfa vs PAD were not significantly different; however, by the day of surgery the epoetin alfa group had significantly higher hemoglobin (130 vs 114 g/L; P < .001), hematocrit (0.408 vs 0.352; P < .001), and reticulocyte count (3.4 vs 2.1 x 10(9) cells per liter; P < .001). These differences remained significant for 1 to 2 days postoperatively. There was no significant difference in the incidence of allogeneic transfusions between groups (28% for epoetin alfa vs 8% for PAD; P = .1383). Both treatments were generally well tolerated. Epoetin alfa appears to be a safe alternative to PAD in patients who are at risk for transfusion in the perioperative period following total knee arthroplasty.
authors.affiliation: Department of Orthopedic Surgery, Kelsey-Seybold Clinic, Baylor College of Medicine, Houston, Texas 77025, USA.
authors.forename: Allen
authors.initials: A
authors.lastname: Deutsch
authors.forename: Janice
authors.initials: J
authors.lastname: Spaulding
authors.forename: Randall E
authors.initials: RE
authors.lastname: Marcus
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019645:Arthroplasty, Replacement, Knee; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001804:Blood Transfusion, Autologous; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care; D011446:Prospective Studies; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa